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Abstract  The  use  of  tyrosine  kinase  inhibitors  (TKIs)  for  the  treatment  of  chronic  myeloid
leukemia  has  signiﬁcantly  altered  the  prognosis  of  this  disease,  enabling  close  to  normal  life
expectancy.
Despite  their  undeniable  beneﬁts,  the  use  of  TKIs  is  associated  with  an  increased  risk  of  side
effects  on  the  cardiovascular  system,  particularly  of  atherothrombotic  events.  It  is  thereforeCardiotoxicity;
Chronic myeloid
leukemia
necessary  to  understand  and  prevent  the  adverse  effects  of  these  drugs,  in  order  to  enable
antileukemic  therapy  to  continue  and  to  minimize  patients’  toxic  exposure. Please cite this article as: Almeida AG, Almeida A, Melo T, Guerra L, Lopes L, Ribeiro P, et al. Novas perspetivas para a abordagem dos
efeitos cardiovasculares dos inibidores da tirosinacinase em doentes com leucemia mieloide crónica. Rev Port Cardiol. 2019;38:1--9.
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This  multidisciplinary  consensus  document,  developed  through  a  collaboration  between  hema-
tologists  and  cardiologists,  aims  to  review  the  cardiovascular  toxicity  associated  with  various
TKIs  and  to  establish  recommendations  for  the  follow-up  of  these  patients.  Measures  are  also
proposed  for  the  assessment  and  reduction  of  cardiovascular  risk  in  these  patients  and  referral
criteria,  and  relevant  drug  interactions  are  discussed.
©  2018  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an










Novas  perspetivas  para  a  abordagem  dos  efeitos  cardiovasculares  dos  inibidores  da
tirosinacinase  em  doentes  com  leucemia  mieloide  crónica
Resumo  O  uso  dos  inibidores  da  tirosina  cínase  (ITC)  para  o  tratamento  da  leucemia  mieloide
crónica alterou  signiﬁcativamente  o  prognóstico  dessa  doenc¸a e  permitiu  uma  esperanc¸a de
vida  praticamente  normal.  Apesar  dos  seus  inegáveis  benefícios,  o  uso  dos  ITC  está  associado
a  um  aumento  do  risco  de  efeitos  colaterais  sobre  o  sistema  cardiovascular,  nomeadamente  no
risco  de  eventos  aterotrombóticos.  Torna-se  por  isso  necessário  conhecer  e  prevenir  os  efeitos
adversos  desses  fármacos  de  modo  a  permitir  a  continuac¸ão  da  terapêutica  antileucémica  e
minimizar  a  toxidade  para  os  doentes.  Este  documento  multidisciplinar,  elaborado  através  de
uma  colaborac¸ão  entre  hematologistas  e  cardiologistas  de  vários  servic¸os  hospitalares  portugue-
ses,  tem  por  objetivo  rever  a  toxidade  cardiovascular  associada  aos  vários  ITCs  e  estabelecer
sugestões para  o  seguimento  desses  doentes.  São  ainda  propostas  medidas  para  a  avaliac¸ão
e reduc¸ão  do  risco  cardiovascular  desses  doentes,  critérios  de  referenciac¸ão  e  discutidas
interac¸ões medicamentosas  relevantes.
©  2018  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este e´  um











































he  treatment  of  chronic  myeloid  leukemia  (CML)  with  tyro-
ine kinase  inhibitors  (TKIs)  has  signiﬁcantly  altered  the
rognosis of  this  disease,  enabling  ﬁve-year  survival  of  over
0% with  the  latest-generation  TKIs.1--3
The  increased  survival  made  possible  by  these  new  ther-
pies, which  now  enable  life  expectancy  close  to  that  of
he general  population,  has  raised  problems  arising  from  the
otential impact  on  long-term  prognosis  of  the  side  effects
f these  new  drugs,  particularly  on  the  cardiovascular  sys-
em. Increases  have  been  reported  in  cardiovascular  events
ssociated with  TKIs,  especially  with  second-generation
gents.4 These  side  effects  mainly  consist  of  thrombotic
rterial events,  and  so  it  is  essential  to  assess  cardiovascular
isk factors  and  to  apply  cardiovascular  prevention  meas-
res. However,  analysis  of  cardiovascular  complications
ssociated with  TKIs  is  hampered  by  the  fact  that  CML  mainly
ccurs in  an  age-group  in  whom  cardiovascular  disease
nd risk  factors  are  already  highly  prevalent.  Furthermore,
ost clinical  trials  on  the  efﬁcacy  and  safety  of  these  new
rugs exclude  subjects  with  known  cardiovascular  disease,
eaning that  the  effects  of  TKIs  on  populations  with  exist-
ng disease  are  unknown.  Finally,  analysis  of  side  effects




ivents  over  a  relatively  short  follow-up;  there  have  so  far
een no  prospective  studies  assessing  the  effects  of  TKIs  on
entricular and  vascular  function.5
As  well  as  the  BCR-ABL  protein  that  causes  CML,  TKIs
lso inhibit  other  kinases  including  PDGFR,  c-Kit  and  Src  that
re also  expressed  in  non-hematopoietic  cells,  and  are  thus
esponsible for  non-hematological  side  effects.
Of  the  ﬁve  TKIs  currently  available  for  the  treatment  of
ML, imatinib  was  the  ﬁrst  and  for  years  was  considered
he standard  of  care.  However,  cases  of  resistance  to  or
ntolerance of  imatinib  led  to  the  development  of  new  TKIs,
hich are  more  potent  inhibitors  of  BCR-ABL  but  have  dif-
erent toxicity  proﬁles.  The  ﬁrst  of  these  second-generation
gents were  dasatinib  and  nilotinib,  which  have  a  stronger
herapeutic effect  than  imatinib  and  are  therefore  now  con-
idered ﬁrst-line  treatment.6 The  other  TKIs  are  used  less
requently: bosutinib  is  mainly  prescribed  as  a  third-line
reatment, while  ponatinib  is  indicated  for  speciﬁc  BCR-ABL
utations.
The toxicity  proﬁles  of  the  three  most  used  agents  --
matinib, dasatinib  and  nilotinib  --  differ  signiﬁcantly.  It  is
mportant to  understand  their  effects,  to  identify  patients
t higher  risk,  and  to  undertake  appropriate  preventive  and























































vTyrosine  kinase  inhibitors  in  chronic  myeloid  leukemia  
Cardiovascular side effects of tyrosine kinase
inhibitors
The  cardiovascular  side  effects  of  TKIs  are  not  manifesta-
tions of  a  drug  class  effect  but  are  in  fact  speciﬁc  to  each
agent. Given  the  short  time  that  some  of  the  new  TKIs  have
been available,  it  may  be  that  only  long-term  use  will  enable
a thorough  assessment  of  all  their  side  effects.
However,  in  general,  TKI  therapy  may  result  in  changes  in
the QT  interval,  as  described  below  for  each  of  the  drugs  in
this class.  It  is  recommended  that  the  QT  interval  should  be
measured on  the  electrocardiogram  (ECG)  before  beginning
treatment with  any  TKI  and  should  be  monitored  regularly
thereafter. In  the  absence  of  more  speciﬁc  data,  we  suggest
that an  ECG  be  performed  at  three  and  at  12  months  after
beginning treatment  (Table  1).  In  addition,  patients  should
be screened  for  electrolytic  abnormalities  such  as  hypomag-
nesemia and  hypokalemia,  which  may  increase  the  risk  for
arrhythmias.
Imatinib
Heart  failure  was  reported  in  initial  non-controlled  stud-
ies on  imatinib.  In  an  in-vitro  study,  imatinib  affected  the
mitochondrial membrane  potential  and  cellular  ultrastruc-
ture, inducing  apoptosis.7 Subsequent  analyses  of  larger
populations in  multicenter  studies  found  no  increase  in  the
incidence of  heart  failure  above  that  expected  for  the  age-
group and  associated  comorbidities.5 In  a  review  of  1276
patients receiving  imatinib,  most  of  those  who  developed
heart failure  had  previous  medical  conditions  predisposing
to the  disease.8 Another  effect  of  imatinib  is  ﬂuid  retention,
but this  has  little  clinical  repercussion  and  pleural  effusion  is
very rare.  Among  the  recommendations  for  patients  treated
with imatinib  is  cardiac  monitoring  in  cardiology  consulta-
tions in  patients  with  prior  heart  disease.
Dasatinib
Dasatinib  is  associated  with  pleural  or  pericardial  effusion
in 20%  of  patients.9,10 A  different  TKI  should  be  considered
in patients  at  risk  of  pleural  effusion,  especially  those  with
a history  of  pulmonary  disease  or  congestive  heart  failure.
Pulmonary hypertension  is  another  complication  found  with
dasatinib, observed  in  0.35%  of  cases,10,11 and  so  alternative
TKIs should  be  used  in  patients  with  pre-existing  pulmonary
hypertension. In  rare  cases  (<1%)  QT  interval  prolongation
may occur  in  patients  treated  with  dasatinib.
Nilotinib
Prolonged  QT  has  also  been  described  as  being  among  the
side effects  of  nilotinib.12 However,  none  of  the  published
studies report  prolongation  of  corrected  QT  interval  (QTc)
of >500  ms,  which  demonstrates  that  nilotinib  is  safe  in  this
regard.13 As  pointed  out  above,  baseline  and  follow-up  moni-
toring of  the  ECG  is  recommended;  care  should  also  be  taken
when administering  antiarrhythmics  or  other  agents  that






One of  the  most  discussed  cardiovascular  toxic  effects  of
econd-generation TKIs  is  the  increase  in  thrombotic  arterial
vents. An  analysis  of  Swedish  population-based  registries
evealed that  CML  itself  increases  the  frequency  of  cardio-
ascular events.14 The  second-generation  TKIs,  nilotinib  and
asatinib, are  also  associated  in  clinical  trials  with  a  higher
ardiovascular event  rate  than  imatinib,4 as  demonstrated
n one  study  in  which  the  incidence  of  thrombotic  arterial
vents with  dasatinib  was  5%  compared  to  2%  with  imatinib
nd was  15.9%  and  10%  with  doses  of  400  mg  and  300  mg
f nilotinib,  respectively,  compared  to  2.5%  with  imatinib.
uch events  are  even  more  frequent  with  ponatinib,5 with
heir incidence  reaching  17.5%.  In  this  context,  it  should  be
ointed out  that  although  second-generation  TKIs  are  more
ften linked  to  thrombotic  events  in  the  above-cited  trials,
ssociated mortality  was  no  higher  in  the  second-generation
rm of  these  trials  than  in  the  imatinib  arm,  while  mortality
aused by  progression  of  CML  was  higher  in  patients  receiv-
ng imatinib  than  in  those  receiving  dasatinib  or  nilotinib,
emonstrating the  importance  of  effective  antileukemic
ction in  these  patients.  Large  retrospective  multicenter
tudies identiﬁed  older  age  and  metabolic  disorders  such  as
ypercholesterolemia or  diabetes  as  major  risk  factors  for
he development  of  peripheral  arterial  disease.15 In  an  anal-
sis that  included  data  from  the  IRIS,  TOPS,  and  ENESTnd
rials, 92%  of  patients  with  peripheral  arterial  occlusive
isease had  cardiovascular  risk  factors  including  diabetes,
yslipidemia, hypertension,  older  age  and  smoking.16 In
he ENESTnd  trial,  there  was  at  least  one  risk  factor  for
therosclerosis prior  to  therapy  in  85%  of  patients  with  acute
oronary syndrome,  while  another  study  revealed  a  signiﬁ-
ant association  between  ischemic  accident  and  cholesterol
evels and  other  cardiovascular  risk  factors.17
While  the  known  metabolic  effects  of  nilotinib,  aggra-
ated by  the  presence  of  hyperglycemia  and  hypercholes-
erolemia, may  increase  the  frequency  of  cardiovascular
vents, it  should  be  borne  in  mind  that  the  population  of
atients with  CML  --  whose  mean  age  is  67  years  --  are  already
t signiﬁcant  risk  of  ischemic  accidents,  not  only  because
f their  age,  but  due  to  the  accumulation  of  risk  factors.
here is  accordingly  debate  whether  such  events  are  merely
art of  these  patients’  natural  history  or  are  in  fact  sec-
ndary to  nilotinib  therapy.13 Furthermore,  nilotinib  may  act
n addition  to  established  cardiovascular  risk  factors  or  other
omorbidities by  direct  vascular  effects,  due  to  its  inter-
ction with  discoidin  domain  receptor  1,  or  by  metabolic
ffects on  blood  glucose  and  cholesterol  levels,  all  of  which
ontribute to  occlusive  atherosclerotic  disease.  It  has  also
een suggested  that  pre-existing  subclinical  vascular  disease
efore beginning  therapy  may  be  underestimated.
Breccia  et  al.18 recently  performed  a  retrospective  anal-
sis of  CML  patients  treated  with  nilotinib.  Retrospectively
pplying the  SCORE  chart  for  cardiovascular  risk  estimation
roposed by  the  European  Society  of  Cardiology  (the  version
or low-risk  European  countries  including  Portugal),19 they
lassiﬁed patients  before  beginning  nilotinib  and  after
ollow-up as  low  (<1%),  moderate  (1-5%),  high  (5-10%)  and
ery high  (>10%)  risk,  on  the  basis  of  age,  gender,  choles-
erol level,  systolic  blood  pressure,  smoking,  diabetes,
enal failure,  obesity,  and  previous  cardiovascular  disease.
he cumulative  incidence  of  atherosclerotic  events  at  48









Table  1  Recommendations  for  initial  assessment  and  follow-up  in  patients  undergoing  tyrosine  kinase  inhibitor  therapy.
Baseline  7  da 1  m  3  m  6  m  Follow-up







Baseline  and  follow-up:
angina, intermittent
claudication
X  X  X  X  X
Assessment  and




X  X  X  X  X
Calculation  of  overall
cardiovascular  risk  (ESC
SCORE)
X




X  X  X  X  Patients  with  renal
failure  are
considered  at  high
CV risk
ECG  X  X  X  X  Assess  QTc
Screen  for  signs  of
prior MI
Assessment  of  blood
glucose, HbA1c  and  lipid
proﬁle
X X  X  X
TTE X  X  Consider,  even




function with  TKIs
a Recommended by the US Food and Drug Administration.
b Until disease stabilization.
CV:  cardiovascular; d: days; ECG: electrocardiogram; ESC: European Society of Cardiology; HbA1c: glycated hemoglobin; m: months; MI: myocardial infarction; QTc: corrected QT interval;












Table  2  Classiﬁcation  of  overall  cardiovascular  risk  and  recommendations  for  each  risk  category.
Risk  category Characteristics  Recommendations
Low  (<1%) No  CV  disease  and  overall  risk  <1%
according  to  SCORE
Adopt healthy  lifestyle  (diet,
exercise, smoking  cessation)
Intermediate (≥1%  and  <5%) No  CV  disease  and  overall  risk  ≥1%
and  <5%  according  to  SCORE
Correct  risk  factors
Screen for  symptoms  or  signs  of  CV
disease  (coronary,  cerebrovascular,
peripheral arterial)
High (≥5%  and  <10%) No CV  disease  and  overall  risk  ≥5%
and  <10%  according  to  SCORE
Correct  risk  factors  with  specialist
support
Screen  for  clinical  evidence  of  CV
disease  (coronary,  cerebrovascular,
peripheral)
Consider a  statin
Very high  (≥10%) Evidence  of  CV  disease  (current  or
previous)  or  overall  risk  >10%
according to  SCORE
Correct risk  factors
Treat CV  disease
Consider  cardiology  consultation
Based on the SCORE charts of the European Society of Cardiology16 and the guidelines of the Portuguese Directorate-General of Health (Appendices 1 and 2).









Table  3  Drugs  that  can  be  used  in  association  with  tyrosine  kinase  inhibitors  to  control  cardiovascular  risk  factors.
Risk  factor  Drug  class  Drugs  Comments




Pravastatin  and  pitavastatin  do  not
affect  cytochrome  P450
Monitor CK  levels
Simvastatin  and  lovastatin  should  be
avoided




















Monitor  heart  rate  in  patients  taking




Diabetes Oral  antidiabetics  Metformin  (recommended  as  initial
treatment)














PTyrosine  kinase  inhibitors  in  chronic  myeloid  leukemia  
with  a  greater  incidence  of  ischemic  events,  none  of  which
occurred in  the  low-risk  group.  This  study  suggests  that
atherosclerotic risk  factors  must  be  detected  early  and
throughout the  treatment  period  in  order  to  avoid  ischemic
events, and  that  the  patient  should  be  asked  about  symp-
toms of  angina  and  intermittent  claudication  at  every
consultation.
The majority  of  studies  on  the  effect  of  nilotinib  (and
also dasatinib  and  imatinib)  on  ventricular  function  excluded
patients with  previous  ventricular  dysfunction,  while  oth-
ers did  not  systematically  examine  ventricular  function  by
echocardiography. There  is  thus  no  information  currently
available to  suggest  that  TKIs  signiﬁcantly  affect  ventri-
cular systolic  function  as  assessed  by  ejection  fraction.
One study  found  changes  in  diastolic  function,  implying
that there  may  be  more  subtle  changes  in  ventricular
function.20 There  is  at  the  moment  insufﬁcient  evidence  to
conclude that  ventricular  function  is  signiﬁcantly  affected,
but this  question  should  be  explored  in  further  studies,





Table  4  Drugs  that  prolong  QT  interval.



















































































Other antiarrhythmics  that  prolong  QT  that  are  not
available  to  outpatients  include  quinidine,  procainamide,






The drugs in this table may prolong QTc. Decisions whether to use su
drugs should be used if possible, otherwise QTc should be monitored re
Drugs are listed in alphabetical order within each category together w7
osutinib
ost  studies  on  bosutinib  have  shown  no  increase  in  the
ncidence of  cardiovascular  events.21,22 However,  bosutinib
nhibits signaling  pathways  that  are  also  inhibited  by  pona-
inib, such  as  the  Src  kinase  family,  and  so  until  the
tiopathogenic mechanisms  of  cardiovascular  toxicity  in
KIs are  completely  elucidated,  patients  taking  bosutinib
hould be  monitored  for  possible  cardiovascular  events.23
ikewise,  most  studies  have  not  found  that  bosutinib  pro-
ongs QTc.  In  a  study  of  288  patients  with  CML,  QTc
rolongation was  found  in  only  two  patients  (>500  ms  in
ne and  >60  ms  in  the  other),23 suggesting  that  the  drug
s safe  but  underlining  the  need  for  electrocardiographic
ssessment  and  monitoring.
onatiniblthough  few  studies  on  ponatinib  have  been  published,  it
ppears to  be  associated  with  a  high  risk  for  cardiovascu-





























































te: tricyclic  antidepressants  are  associated  with  greater  risk












me antiretrovirals:  lopinavir,  nelﬁnavir,  saquinavir
ch drugs should be based on a risk/beneﬁt analysis. Alternative
gularly. Based on Nielsen et al.26 and Li et al.27















































0%  of  cases)  but  also  venous.24 In  additions,  hypertension
s a  frequently  cited  side  effect  of  ponatinib  and  therefore
easures must  be  taken  to  control  blood  pressure.25
uggestions for  assessment and monitoring of
ardiovascular  risk in patients with chronic
yeloid  leukemia treated with tyrosine kinase
nhibitors
n  the  basis  of  currently  available  information,  we  propose
n algorithm  for  assessment  (Appendices  1  and  2)  and  mon-
toring (Tables  1--4)  of  patients  with  CML  treated  with  TKIs.
onclusions
rrespective  of  the  patient’s  comorbidities,  there  are  no
bsolute contraindications  to  any  of  the  TKIs.
The  aim  should  be  to  strike  a  balance  between  maxi-
um efﬁcacy  and  minimum  toxicity.  However,  as  the  drug’s
ntileukemic effectiveness  is  the  main  concern  in  advanced
isease, this  takes  precedence  over  its  toxicity  proﬁle.
For  patients  at  very  high  cardiovascular  risk  recently
iagnosed with  chronic  phase  CML,  imatinib  and  dasatinib
re currently  the  preferred  therapeutic  options.  Nilotinib  is
ot recommended  for  these  patients  and  is  only  indicated
fter careful  assessment  of  cardiovascular  risk  factors,  dis-
ase severity  and  the  expected  therapeutic  beneﬁt.  In
atients at  low  or  moderate  cardiovascular  risk,  any  of  the
KIs can  be  prescribed.
Ponatinib should  not  be  prescribed  for  patients  previously
iagnosed with  peripheral  arterial  disease,  and  nilotinib  is
ot recommended  in  cases  of  known  severe  peripheral  dis-
ase, although  it  may  be  considered  if  the  disease  is  mild  to
oderate after  assessment  of  risks  and  beneﬁts.5
onﬂicts of interest
he  authors  have  no  conﬂicts  of  interest  to  declare.
ppendix A. Supplementary data
upplementary  data  associated  with  this  article  can  be
ound, in  the  online  version,  at  doi:10.1016/j.repce.
017.10.017.
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